三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
针对TTR疾病(ATTR-PN及ATTR-CM)的疗法当前FDA批准新药状态
针对TTR疾病(ATTR-PN及ATTR-CM)的疗法当前FDA批准新药状态
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:368KB
图片尺寸:2305*493
同报告图片
/
4
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
所属报告:
艾拉伦制药(ALNY.US)-美股公司研究报告:管理层交流反馈:Amvuttra全球商业化强劲推进及主要临床项目进展-251127(13页).pdf
打包全文图表
相关数据
到2040年美国FDA批准的中国原创新药占比
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
收藏
行业数据
2026-06-11
原图定位
查看详情
美国FDA各年度批准NME药物与生物药数量
收藏
行业数据
2026-05-25
原图定位
查看详情
美国FDA药物评价与研究中心受理的IND申请
收藏
行业数据
2026-04-08
原图定位
查看详情
图表11FDA获批KRASG12C抑制剂的全球销售额(百万美元)
收藏
行业数据
2026-02-25
原图定位
查看详情
图 26 美国食品和药物管理局(FDA)在2020年开始实施RACE法案,以确保更多癌症药物试验包括儿童人群
收藏
行业数据
2026-02-13
原图定位
查看详情
**TABLE 5. FDA-approved Immunotherapeutics to Treat Pediatric Cancers (2015–2025)**
收藏
行业数据
2026-02-13
原图定位
查看详情
**TABLE 4 FDA-approved Molecularly Targeted Therapies to Treat Pediatric Cancers (2015–2025)**
收藏
行业数据
2026-02-13
原图定位
查看详情
表 5 FDA批准的免疫治疗药物用于治疗儿科癌症(2015–2025)
收藏
行业数据
2026-02-13
原图定位
查看详情
Figure 2 FDA-approved therapeutics with CDx, including novel oncological therapies (1997-2024)
收藏
行业数据
2026-02-13
原图定位
查看详情
表4 FDA批准的分子靶向疗法用于治疗儿童癌症(2015–2025)
收藏
行业数据
2026-02-13
原图定位
查看详情
2018-2024年FDA批准的创新抗体药物分类(个)
fCDliIbnsbsgICB8IOaVsOmHj++8iOS4qu+8iSB8IOWNoOavlCAgIHwKfCAtLS0tLS0gfCAtLS0tLS0tLS0tIHwgLS0tLS0tIHwKfCDltYzlkIjkvZMgfCAzICAgICAgICAgIHwgNC42JSAgIHwKfCDlhajkurrmupAgfCAyMiAgICAgICAgIHwgMzMuOCUgIHwKfCDkurrmupDljJYgfCA0MCAgICAgICAgIHwgNjEuNSUgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuOaLm+iCoeS5pu+8jOW8l+iLpeaWr+eJueaymeWIqeaWh++8jOWbveazsOa1t+mAmuivgeWIuOeglOeptg==
收藏
行业数据
2026-01-27
原图定位
查看详情
2018-2024年FDA批准的全人源抗体制备技术分
fCDmioDmnK/nsbvliKsgICAgICAgfCDmlbDph4/vvIjkuKrvvIkgfAp8LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18Cnwg6L2s5Z+65Zug5bCP6byg5oqA5pyvIHwgOSAgICAgICAgICB8Cnwg5Zms6I+M5L2T5bGV56S65oqA5pyvIHwgNyAgICAgICAgICB8Cnwg5YW25a6D5oqA5pyvICAgICAgIHwgNiAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrlhazlj7jmi5vogqHkuabvvIzlvJfoi6Xmlq/nibnmspnliKnmlofvvIzlm73ms7DmtbfpgJror4HliLjnoJTnqbY=
收藏
行业数据
2026-01-27
原图定位
查看详情
FDA拟禁用合成色素种类在欧盟和中国使用情况
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
收藏
行业数据
2026-01-15
原图定位
查看详情
2018-2024各年NMPA及FDA合批准的抗
fCDlubTku70gfCDmipfkvZPoja/mlbDph4/vvIjkuKrvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwKfCAyMDE4IHwgMjAgICAgICAgICAgICAgICB8CnwgMjAxOSB8IDE2ICAgICAgICAgICAgICAgfAp8IDIwMjAgfCAxNiAgICAgICAgICAgICAgIHwKfCAyMDIxIHwgMjEgICAgICAgICAgICAgICB8CnwgMjAyMiB8IDIxICAgICAgICAgICAgICAgfAp8IDIwMjMgfCAyMyAgICAgICAgICAgICAgIHwKfCAyMDI0IHwgMzIgICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrnmb7lpaXotZvlm77mi5vogqHkuabvvIxGREHvvIxDREXvvIzlvJfoi6Xmlq/nibnmspnliKnmlofvvIzlm73ogZTmsJHnlJ/or4HliLg=
收藏
行业数据
2026-01-05
原图定位
查看详情
2018-2024FDA批准的创新抗体药分类
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
收藏
行业数据
2026-01-05
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
心肌病(ATTR-CM),目前正处于CARDIO-TTRansform三期临床试验。该试验招募1,400名受试者,已于2023年7月完成入组。艾拉伦管理层认为,此产品对Amvuttra构成威胁有限,因为两者已在ATTR-PN市场展开竞争,且Amvuttra已占据领先地位。
行业数据
原图定位
当前图表所属:
艾拉伦制药(ALNY.US)-美股公司研究报告:管理层交流反馈:Amvuttra全球商业化强劲推进及主要临床项目进展-251127(13页).pdf
NucresiranATTR-CMTRITON-CM三期设计
艾拉伦制药对Vutrisiran未来支付比例指引
三大ATTR-CM核心品牌(Tafa/Attruby/Vutrisiran)及艾拉伦制药Patisiran过往季度销售
Amvuttra在ATTR-CM最大竞争对手Tafamidis(Vyndamax及Vyndaqel)销量及增长趋势
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》